District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
INTIBIA Pivotal Study
NCT05250908
Recruiting
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Gender:
All
Ages:
Between 22 years and 80 years
Trial Updated:
02/05/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Urinary Incontinence, Urge, Urinary Bladder, Overactive, Urinary Bladder Diseases, Urologic Diseases, Lower Urinary Tract Symptoms, Urological Manifestations
Register for Updates
Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis
NCT05180240
Recruiting
Multi-center, double-blind, placebo-controlled, parallel group design. Patients with myocarditis will be screened and, if eligible, randomized within 10 days of the diagnostic CMR to CardiolRx or placebo. CardiolRx is pharmaceutically produced Cannabidiol and is free of tetrahydrocannabinol (THC<5 ppm). The treatment period is 12 weeks; a last follow-up visit is scheduled one week after the last treatment, 13 weeks after randomization. Study assessments include Cardiac Magnetic Resonance imagin... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
02/05/2024
Locations: MedStar Heart and Vascular Institute, Washington, District of Columbia
Conditions: Acute Myocarditis
Register for Updates
Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer
NCT05050162
Recruiting
This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head and neck cancer. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma, Advanced Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary
Register for Updates
Acute Concussion and Melatonin
NCT04731974
Recruiting
In this study, the investigator plans a randomized trial of melatonin versus placebo post acute pediatric concussion. The investigator hypothesizes that patients with acute concussions managed with melatonin will have improved sleep, decreased depressive symptoms, decreased risk of prolonged concussion symptoms and faster resolution of concussion symptoms.
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
02/05/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Concussion, Mild, Concussion, Brain, Pediatric ALL
Register for Updates
DMSO Cryopreserved Platelets in Cardiopulmonary Bypass Surgery (CRYPTICS)
NCT04709705
Recruiting
A randomized, parallel group, active comparator-controlled trial to evaluate the non-inferiority or superiority of Cryopreserved Platelets with Liquid Stored Platelets in controlling blood loss in patients undergoing Cardiopulmonary Bypass Surgery.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: Cardiac Surgery
Register for Updates
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: George Washington University Medical Center, Washington, District of Columbia
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116
Recruiting
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blin... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
02/05/2024
Locations: Georgetown University Medical Center - Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Locally Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
NCT06015724
Recruiting
The goal of this clinical trial is to test the safety and tolerability of anti-CD38 monoclonal antibody (mAb), daratumumab, in combination with KRAS vaccine (Targovax TG-01/Stimulon QS-21) when given with anti-PD-1 (programmed cell death protein 1) mAb (nivolumab) in patients with advanced non-small cell lung cancer (NSCLC) or pancreatic ductal adenocarcinoma (PDAC). The main questions it aims to answer are: How well does daratumumab and nivolumab, when given with a vaccine, control or stop the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia
Conditions: Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
Register for Updates
The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer
NCT05780814
Recruiting
The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CBT-I) prior to behavioral weight loss (CBT-I+BWL) is superior to a sleep education control (EDU) condition followed by behavioral weight loss (EDU+BWL). The investigators will measure outcomes at baseline, 8 weeks (after completing CBT-I or EDU and prior to BWL)... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia
Conditions: Breast Cancer, Insomnia, Weight Gain
Register for Updates
Respiratory Virus Hospitalization Study (FLU 003 Plus)
NCT01056185
Recruiting
Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to estimate rates of morbidity and mortality and to examine predictors of severity among participants with 2009 H1N1 infection. In 2011, as surveillance indicated that 2009 H1N1 virus was co-circulating with other seasonal influenza A and B viruses worldwide, the protocol was expanded to include other influenza A subtypes and influenza B viruses. The current version o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/01/2024
Locations: George Washington Medical Faculty Associates, Washington, District of Columbia
Conditions: Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Register for Updates
Confirmation of Diet as a Treatment for Gulf War Illness
NCT05675878
Recruiting
This clinical trial aims to confirm previous findings from a smaller study which demonstrated significant improvements in all symptoms among veterans with Gulf War Illness after one month on the dietary intervention. The main objectives of this study are: 1) to confirm previous findings of treatment response to the diet in a larger and more diverse group; 2) to examine how changes in the nervous system may be the reason for improvement; and 3) to identify markers which change in the blood after... Read More
Gender:
All
Ages:
Between 50 years and 75 years
Trial Updated:
01/31/2024
Locations: American University, Washington, District of Columbia
Conditions: Gulf War Syndrome, Gulf War Illness
Register for Updates
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697
Recruiting
The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Georgetown University Medical Center ( Site 1002), Washington, District of Columbia
Conditions: Renal Cell Carcinoma
Register for Updates